Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Singular Genomics Systems, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
4
| Ropp Sam (Chief Commercial Officer) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.5355, valued at
$53.6k
|
|
| 08/15/2023 |
4
| Kamdar Kim P. (Director) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Sold 353,657 shares
@ $0.5955, valued at
$210.6k
Sold 77,991 shares
@ $0.5696, valued at
$44.4k
Sold 200,000 shares
@ $0.5348, valued at
$107k
|
|
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
SC 13G/A
| Flynn James E reports a 7.4% stake in Singular Genomics Systems, Inc. |
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"### EX-99.1 Singular Genomics Systems, Inc. Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 505 $ - $ 1,368 $ - Cost of revenue 597 - 1,404 - Gross margin - - Operating expenses: Research and development 12,624 12,061 24,854 22,707 Selling, general and administrative 14,887 12,182 28,091 23,556 Total operating expenses 27,511 24,243 52,945 46,263 Loss from operations Other income : Interest expense Interest and other income 2,295 428 4,299 584 Total other income 2,025 261 3,770 275 Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 72,510,020 70,779,326 72,218,280 70,893,059 EX-99.1 Singular Genomics Systems, Inc. Bala..." |
|
| 08/08/2023 |
4
| Eisenberg Marcia (Director) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Granted 148,000 options to buy
@ $0.747, valued at
$110.6k
|
|
| 08/08/2023 |
3
| Eisenberg Marcia (Director) has filed a Form 3 on Singular Genomics Systems, Inc. |
| 08/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/20/2023 |
8-K
| Quarterly results |
| 05/26/2023 |
4
| Kamdar Kim P. (Director) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Granted 74,000 options to buy
@ $1.06, valued at
$78.4k
|
|
| 05/26/2023 |
4
| Mardis Elaine R (Director) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Granted 74,000 options to buy
@ $1.06, valued at
$78.4k
|
|
| 05/26/2023 |
4
| Pellini Michael J (Director) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.06, valued at
$106k
|
|
| 05/26/2023 |
4
| Ryan Jason (Director) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Granted 74,000 options to buy
@ $1.06, valued at
$78.4k
|
|
| 05/26/2023 |
4
| BARKER DAVID L (Director) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Granted 74,000 options to buy
@ $1.06, valued at
$78.4k
|
|
| 05/18/2023 |
4
| Glezer Eli N. (Chief Scientific Officer) has filed a Form 4 on Singular Genomics Systems, Inc.|
Txns:
| Bought 170,000 shares
@ $0.8172, valued at
$138.9k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended March 31, 2023 2022 Revenue $ 863 $ - Cost of revenue 807 - Gross margin 56 - Operating expenses: Research and development 12,230 10,645 Selling, general and administrative 13,204 11,375 Total operating expenses 25,434 22,020 Loss from operations Other income : Interest expense Interest and other income 2,004 156 Total other income 1,745 14 Net loss $ $ Net loss per share: Basic and diluted net loss per share $ $ Weighted-average shares used to compute basic and diluted net loss per share 71,926,412 71,011,041 EX-99.1 Singular Genomics Systems, Inc. Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 129,283 $ 74,266 Short-term investments 96,790 170,310 Accounts rec..." |
|
| 04/20/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/13/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Revenue $ 765 $ - $ 765 $ - Cost of revenue 789 - 789 - Gross margin - - Operating expenses: Research and development 10,760 9,455 46,199 32,655 Selling, general and administrative 11,746 10,218 47,264 28,624 Total operating expenses 22,506 19,673 93,463 61,279 Loss from operations Other income : Interest expense Change in fair value of convertible promissory notes" |
|
| 02/14/2023 |
SC 13G/A
| Glezer Eli N. reports a 6% stake in Singular Genomics Systems, Inc. |
| 02/14/2023 |
SC 13G/A
| Revelation Alpine, LLC reports a 1.7% stake in Singular Genomics Systems, Inc. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 9.1% stake in Singular Genomics Systems, Inc. |
| 02/01/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
|
|
|